Uno studio del primo umano di KK2223 nei partecipanti con linfoma non hodgkin recidivante o refrattario
Uno studio di fase 1, multicentrico, aperto, non randomizzato, dose-escalation e backfill di KK2223 nei partecipanti con linfoma non hodgkin recidivante o refrattario a cellule T.
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Kyowa Kirin, Inc.
- Numero di telefono: +1-609-919-1100
- Email: KKD.Clinical.82@kyowakirin.com
Luoghi di studio
-
-
-
Bergamo, Italia, 24127
- Non ancora reclutamento
- Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
-
Investigatore principale:
- Giuseppe Gritti
-
Contatto:
- Giuseppe Gritti
- Numero di telefono: 39035269492
- Email: giuseppe_gritti@yahoo.it
-
Bologna, Italia, 40138
- Non ancora reclutamento
- Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
-
Contatto:
- Luigi Zinzani Pier
- Numero di telefono: 390516363680
- Email: pierluigi.zinzani@unibo.it
-
Investigatore principale:
- Luigi Zinzani Pier
-
Torino, Italia, 10126
- Non ancora reclutamento
- AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
-
Contatto:
- Federica Cavallo
- Numero di telefono: 390116334264
- Email: f.cavallo@unito.it
-
Investigatore principale:
- Federica Cavallo
-
-
Torino
-
Candiolo, Torino, Italia, 10060
- Non ancora reclutamento
- Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
-
Investigatore principale:
- Umberto Vitolo
-
Contatto:
- Umberto Vitolo
- Numero di telefono: 390116335934
- Email: umberto.vitolo@ircc.it
-
-
-
-
-
Madrid, Spagna, 28027
- Non ancora reclutamento
- Clinica Universidad de Navarra - Hematología y Hemoterapia
-
Contatto:
- Miguel Canales Albendea
- Numero di telefono: 34917277116
- Email: macanales@unav.es
-
Investigatore principale:
- Migue Canales Albendea
-
-
Barcelona
-
Badalona, Barcelona, Spagna, 8036
- Non ancora reclutamento
- Hospital Clinic De Barcelona - Hematología
-
Investigatore principale:
- Pablo Mozas
-
Contatto:
- Pablo Mozas
- Numero di telefono: 34 93 227 22 71
- Email: mozas@clinic.cat
-
L'Hospitalet de Llobregat, Barcelona, Spagna, 8907
- Non ancora reclutamento
- Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
-
Investigatore principale:
- Eva Domingo Domenech
-
Contatto:
- Eva Domingo Domenech
- Numero di telefono: 34932607822
- Email: edomingo@iconcologia.net
-
-
Navarre
-
Pamplona, Navarre, Spagna, 31008
- Non ancora reclutamento
- Clinica Universidad de Navarra - Hematología
-
Contatto:
- Miguel Canales Albendea
- Numero di telefono: 34917277116
- Email: macanales@unav.es
-
Investigatore principale:
- Miguel Canales Albendea
-
-
-
-
California
-
Duarte, California, Stati Uniti, 91010
- Non ancora reclutamento
- City of Hope
-
Investigatore principale:
- Christina Poh
-
Contatto:
- Christina Poh
- Numero di telefono: 916-734-7131
- Email: cpoh@coh.org
-
Orange, California, Stati Uniti, 92868
- Non ancora reclutamento
- University of California, Irvine Medical Center - Hematology/Oncology
-
Contatto:
- Lauren Pinter Brown
- Numero di telefono: 7144568200
- Email: lpinterb@uci.edu
-
Investigatore principale:
- Lauren Pinter Brown
-
Stanford, California, Stati Uniti, 94305
- Reclutamento
- Stanford University School of Medicine
-
Investigatore principale:
- Youn Kim
-
Contatto:
- Youn Kim
- Numero di telefono: 650-723-7893
- Email: younkim@stanford.edu
-
-
Florida
-
Tampa, Florida, Stati Uniti, 33612
- Non ancora reclutamento
- Moffit Cancer Center
-
Contatto:
- Yumeng Zhang
- Numero di telefono: 844-304-8636
- Email: yumeng.zhang@moffitt.org
-
Investigatore principale:
- Yumeng Zhang
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Non ancora reclutamento
- Emory University Medical Center
-
Investigatore principale:
- Pamela Allen
-
Contatto:
- Pamela Allen
- Numero di telefono: 404-778-2407
- Email: pallen5@emory.edu
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- Non ancora reclutamento
- University of Iowa Health
-
Investigatore principale:
- Eric Mou
-
Contatto:
- Eric Mou
- Numero di telefono: 800-777-8442
- Email: eric-mou@uiowa.edu
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Non ancora reclutamento
- Beth Israel Deaconess Medical Center - Research
-
Contatto:
- Salvia Jain
- Numero di telefono: 617-726-2000
- Email: salvia.jain@mgh.harvard.edu
-
Investigatore principale:
- Salvia Jain
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University School of Medicine - Oncology Hospital - Public
-
Investigatore principale:
- Neha Mehta Shah
-
Contatto:
- Neha Mehta Shah
- Numero di telefono: 314.273-8566
- Email: mehta-n@wustl.edu
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601-2105
- Non ancora reclutamento
- Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
-
Investigatore principale:
- Tatyana Feldman
-
Contatto:
- Tatyana Feldman
- Numero di telefono: 551-996-5900
- Email: tatyana.feldman@hmhn.org
-
-
New York
-
New York, New York, Stati Uniti, 10021-6007
- Reclutamento
- Memorial Sloan Kettering Cancer Center
-
Investigatore principale:
- Jasmine Zain
-
Contatto:
- Jasmine Zain
- Numero di telefono: 212-639-3045
- Email: zainj1@mskcc.org
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106
- Non ancora reclutamento
- University Hospitals Cleveland Medical Center
-
Contatto:
- Kevin Cooper
- Numero di telefono: 216-844-8200
- Email: kevin.cooper@uhhospitals.org
-
Investigatore principale:
- Kevin Cooper
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Non ancora reclutamento
- Oregon Health & Science University
-
Contatto:
- Craig Okada
- Numero di telefono: 503-494-8397
- Email: okadac@ohsu.edu
-
Investigatore principale:
- Craig Okada
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Non ancora reclutamento
- University of Pennsylvania - Abramson Cancer Center
-
Investigatore principale:
- Stefan Barta
-
Contatto:
- Stefan Barta
- Numero di telefono: 215-728-2674
- Email: Stefan.Barta@pennmedicine.upenn.edu
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- The University of Texas - MD Anderson Cancer Center
-
Investigatore principale:
- Ranjit Nair
-
Contatto:
- Ranjit Nair
- Numero di telefono: 171-379-2860
- Email: rnair@mdanderson.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
- PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
- Availability of tumor tissue (current or archival) is required.
- Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
- ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
- Body weight 40 kg to ≤ 200 kg
- Life expectancy ≥3 months.
- Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
- Restrictions on gamete donation and freezing during and after treatment.
- Ability to provide informed consent and comply with study procedures. -
Exclusion Criteria:
- Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
- Pregnant or breastfeeding females, or those intending pregnancy.
- History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
- Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
- Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
- Use of other investigational drugs within 14 days or 5 half-lives before treatment.
- Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
- Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
- Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
- Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
- Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
- Prolonged QT/QTc interval (e.g., QTcF >480 ms).
- Active second primary malignancies except specified non-exclusionary cases.
- CNS involvement.
- Any condition that may impair compliance or study completion as judged by the Investigator.
- Known hypersensitivity to any excipients in the drug formulation.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Part One (Dose Escalation)
In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design. |
Intravenous infusion |
|
Sperimentale: Part Two (Backfill)
Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment. |
Intravenous infusion |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Lasso di tempo: Through study completion, an average of 1.5 years
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Lasso di tempo: Through study completion, an average of 1.5 years
|
Vital signs (mmHg in Systolic/Diastolic blood pressure) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Lasso di tempo: Through study completion, an average of 1.5 years
|
Pulse rate (beats/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Lasso di tempo: Through study completion, an average of 1.5 years
|
Respiratory Rate (breath/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Lasso di tempo: Through study completion, an average of 1.5 years
|
Temperature (°Celcius) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Lasso di tempo: Through study completion, an average of 1.5 years
|
ECG parameters (PR interval, QRS interval, QT interval, QTc interval) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Lasso di tempo: Through study completion, an average of 1.5 years
|
Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD) |
Through study completion, an average of 1.5 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mean Blood Drug Concentration
Lasso di tempo: Through study completion, an average of 1.5 years
|
The mean drug concentration in the blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the immunogenicity of KK2223.
Lasso di tempo: Through study completion, an average of 1.5 years
|
Incidence of Anti drug antibodies (ADA) in blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Lasso di tempo: Through study completion, an average of 1.5 years
|
% in Overall Response Rate (ORR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Lasso di tempo: Through study completion, an average of 1.5 years
|
% in Compartment Response (if applicable) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Lasso di tempo: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Duration of Response (DOR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Lasso di tempo: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Lasso di tempo: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Response (TTR) |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
Lasso di tempo: Through study completion, an average of 1.5 years
|
The maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
Lasso di tempo: Through study completion, an average of 1.5 years
|
A measure of the overall drug exposure over time |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Lasso di tempo: Through study completion, an average of 1.5 years
|
The time taken to reach the maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
Lasso di tempo: Through study completion, an average of 1.5 years
|
The time required for the drug concentration to decrease by 50% |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Clearance (CL)
Lasso di tempo: Through study completion, an average of 1.5 years
|
Rate of drug elimination from the body |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
Lasso di tempo: Through study completion, an average of 1.5 years
|
Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues |
Through study completion, an average of 1.5 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per tipo istologico
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma non Hodgkin
- Linfoma, cellule T
- Malattie emiche e linfatiche
- Neoplasie
- Linfoma
- Linfoma, cellule T, periferiche
- Linfoma, cellule T, cutaneo
- Malattie del sistema immunitario
- Micosi fungoide
- Sindrome di Sézary
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2223-001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .